Dashboard
Manage Tickers

NTLA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-bath--body-works-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-wednesday
This Bath & Body Works Analyst Is No Longe...
11/12/2025 14:00:27

wolfe-research-downgrades-intellia-therapeutics-to-peer-perform
Wolfe Research Downgrades Intellia Therape...
11/12/2025 12:00:30

Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to Peer Perform.

jones-trading-downgrades-intellia-therapeutics-to-hold
Jones Trading Downgrades Intellia Therapeu...
11/11/2025 19:54:11

Jones Trading analyst Debanjana Chatterjee downgrades Intellia Therapeutics (NASDAQ:NTLA) from Buy to Hold.

this-sps-commerce-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-tuesday
This SPS Commerce Analyst Is No Longer Bul...
11/11/2025 12:05:53

what-21-analyst-ratings-have-to-say-about-intellia-therapeutics
What 21 Analyst Ratings Have To Say About ...
11/11/2025 11:45:05

evercore-isi-group-downgrades-intellia-therapeutics-to-in-line-lowers-price-target-to-8
Evercore ISI Group Downgrades Intellia The...
11/11/2025 10:15:28

Evercore ISI Group analyst Jonathan Miller downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In-Line and low...

intellia-therapeutics-presents-follow-up-data-from-ongoing-phase-1-clinical-trial-of-investigational-product-nex-z-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy-at-aha-2025
Intellia Therapeutics Presents Follow-Up D...
11/10/2025 20:22:20

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up...

truist-securities-reiterates-buy-on-intellia-therapeutics-lowers-price-target-to-14
Truist Securities Reiterates Buy on Intell...
11/10/2025 16:45:43

Truist Securities analyst Joon Lee reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target fro...

hc-wainwright--co-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-15
HC Wainwright & Co. Maintains Buy on Intel...
11/10/2025 12:32:10

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the p...

reported-saturday-intellia-therapeutics-pooled-phase-12-data-show-97-of-patients-attack-free-and-ltp-free-after-one-time-50mg-dose-of-lonvoguran-ziclumeran-in-hereditary-angioedema
Reported Saturday, Intellia Therapeutics P...
11/10/2025 08:56:25

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cu...

chardan-capital-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-26
Chardan Capital Maintains Buy on Intellia ...
11/07/2025 23:10:46

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...

rbc-capital-maintains-sector-perform-on-intellia-therapeutics-lowers-price-target-to-9
RBC Capital Maintains Sector Perform on In...
11/07/2025 19:10:23

RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Sector Perform and lowers the price targe...

wells-fargo-maintains-equal-weight-on-intellia-therapeutics-lowers-price-target-to-12
Wells Fargo Maintains Equal-Weight on Inte...
11/07/2025 18:56:23

Wells Fargo analyst Yanan Zhu maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-Weight and lowers the price target ...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
11/07/2025 17:05:53

barclays-maintains-overweight-on-intellia-therapeutics-lowers-price-target-to-14
Barclays Maintains Overweight on Intellia ...
11/07/2025 15:28:29

Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target from ...

wedbush-maintains-neutral-on-intellia-therapeutics-lowers-price-target-to-7
Wedbush Maintains Neutral on Intellia Ther...
11/07/2025 15:08:52

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target ...

citizens-maintains-market-outperform-on-intellia-therapeutics-lowers-price-target-to-21
Citizens Maintains Market Outperform on In...
11/07/2025 13:52:54

Citizens analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the price...

jp-morgan-downgrades-intellia-therapeutics-to-underweight-lowers-price-target-to-5
JP Morgan Downgrades Intellia Therapeutics...
11/07/2025 12:15:03

JP Morgan analyst Brian Cheng downgrades Intellia Therapeutics (NASDAQ:NTLA) from Neutral to Underweight and lowers the pric...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
11/07/2025 12:05:44

block-posts-downbeat-q3-results-joins-archer-aviation-draftkings-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Block Posts Downbeat Q3 Results, Joins Arc...
11/07/2025 11:29:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION